What is Survanta, and what is it used for?
Survanta is a synthetic lung surfactant medicine used to treat respiratory distress syndrome (RDS) in premature babies. It helps keep the lungs’ air sacs (alveoli) from collapsing by replacing or supplementing natural surfactant, which is usually missing or insufficient in preterm infants [1].
How is Survanta given in newborns?
Survanta is administered directly into the lungs (intratracheal instillation) as a treatment for neonatal RDS. Dosing and timing are guided by the infant’s condition and clinical response, typically given through a clinician-managed airway procedure in a hospital setting [1].
What does Survanta cost, and does insurance typically cover it?
Pricing can vary by country, hospital contract, and formulation size; the public information available depends on the market. In many settings, it is covered for the approved pediatric indication (premature infant RDS), but coverage decisions and copays depend on the specific insurer and local formularies [2].
Are there alternatives to Survanta for neonatal RDS?
Yes. Multiple surfactant products are used for neonatal RDS, and hospitals may choose between them based on availability, clinical protocols, and regulatory approvals in their region. Patients and clinicians generally compare options based on product labeling, dosing schedules, and outcomes reported in studies or clinical guidance [1][2].
What side effects and risks do parents ask about?
Common concerns with intratracheal surfactant therapies in newborns can include procedure-related issues (since the medicine is delivered into the airway) and possible breathing or oxygenation changes after dosing. The specific risk profile is based on the product’s prescribing information and the infant’s underlying condition [1].
How does Survanta work in the lungs?
Surfactant reduces surface tension inside alveoli, helping them stay open for breathing. Preterm infants often lack adequate surfactant production, which contributes to alveolar collapse and impaired gas exchange in neonatal RDS. Survanta is designed to provide this functional surfactant activity in the lungs [1].
What to check in the prescribing information
Key details to look for include the approved indication (neonatal RDS), administration method (intratracheal), dosing guidance, and the listed contraindications and warnings. These are provided in the product’s official label for your country/market [1].
Sources
[1] https://www.drugs.com/survanta.html
[2] https://www.drugs.com/price-guide/survanta